Gainers
- Celularity CELU shares moved upwards by 36.8% to $1.98 during Thursday's regular session. The market value of their outstanding shares is at $43.6 million. As per the news, the Q2 earnings report came out today.
- Coherus BioSciences CHRS shares moved upwards by 31.25% to $0.95. The market value of their outstanding shares is at $109.4 million. As per the press release, Q3 earnings came out yesterday.
- Emergent BioSolutions EBS shares increased by 30.76% to $12.03. The market value of their outstanding shares is at $630.3 million. As per the news, the Q3 earnings report came out yesterday.
- Ensysce Biosciences ENSC stock increased by 29.17% to $0.71. The market value of their outstanding shares is at $10.6 million.
- Psyence Biomedical PBM stock rose 23.03% to $0.08. The market value of their outstanding shares is at $4.0 million.
- Myomo MYO shares rose 19.61% to $5.0. The company's market cap stands at $151.1 million. As per the press release, Q3 earnings came out yesterday.
Losers
- Xilio Therapeutics XLO shares fell 28.7% to $0.92 during Thursday's regular session. The company's market cap stands at $40.4 million.
- Dentsply Sirona XRAY shares fell 24.69% to $18.06. The company's market cap stands at $3.6 billion. As per the news, the Q3 earnings report came out today.
- Personalis PSNL shares declined by 19.54% to $4.49. The market value of their outstanding shares is at $296.0 million. As per the news, the Q3 earnings report came out yesterday.
- Axogen AXGN shares decreased by 17.75% to $12.61. The company's market cap stands at $552.6 million. The company's, Q3 earnings came out today.
- Harvard Bioscience HBIO shares fell 17.56% to $2.33. The market value of their outstanding shares is at $101.3 million. As per the press release, Q3 earnings came out today.
- Clover Health Investments CLOV shares decreased by 16.41% to $3.64. The market value of their outstanding shares is at $1.8 billion. As per the press release, Q3 earnings came out yesterday. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in